Do Insurance Policies Cover Weight Loss Injections in the UK?

Why most private health insurance policies don't cover weight loss injections

This is a question our prescribers hear most weeks, and the honest answer is frustrating for many people: standard UK private medical insurance was not designed with weight management medicines in mind. Conditions such as obesity have historically been excluded from PMI (private medical insurance) cover on the grounds that they are considered lifestyle-related rather than acute illnesses requiring intervention. The position has been slow to change, even as clinical evidence mounts that medicines like tirzepatide and semaglutide produce sustained, meaningful weight reduction far beyond anything diet alone can achieve.

Some employer group health schemes (particularly larger corporate schemes administered through providers like Bupa, AXA Health or Vitality) have begun exploring cover for GLP-1 medicines as part of occupational health packages. A small number of top-tier plans now include it as an optional rider or through specialist pathways. If you hold private health insurance through your employer, it is worth reading your policy schedule carefully and asking your HR team or insurer directly, because the landscape is genuinely evolving.

Critical point: even where a policy does cover weight management medicine, the insurer will almost always require a clinical prescription from a registered prescriber. Cover does not mean automatic access — the medicine remains prescription-only regardless of who is funding it, and a prescriber's independent assessment is the starting point.

What the NHS route actually requires, and why private treatment fills the gap

The NHS does fund tirzepatide for weight management under NICE technology appraisal TA1026, published in December 2024. The current criteria, however, are deliberately phased. As of mid-2026, NHS tirzepatide is available to adults with a BMI of 40 or above who also have four or more of a defined set of weight-related conditions, including type 2 diabetes, high blood pressure, dyslipidaemia, obstructive sleep apnoea and cardiovascular disease. A second cohort covering BMI 35–39.9 with four or more of those conditions activated in June 2026. Further cohorts are expected in 2027. Ethnic-background adjustments apply, with thresholds 2.5 kg/m² lower for some groups.

That leaves a substantial proportion of people who meet the licensed eligibility criteria for private treatment (BMI of 30 or above, or 27 or above with at least one weight-related condition) but who sit outside the current NHS threshold. For them, private prescription is the realistic near-term option. If cost is a barrier, it may help to understand exactly what a private prescription includes; our weight loss injections finance page covers the breakdown of typical costs across providers and what to look for in a transparent pricing structure. Separately, Wegovy (semaglutide) is available on the NHS through specialist weight management services under NICE TA875, though waiting times in many areas are considerable.

The travel insurance question: a different kind of cover

Travel insurance and private health insurance are separate products with separate rules, and the distinction matters if you take weight loss injection medicines on holiday or for extended trips abroad. Standard travel policies typically require you to declare pre-existing medical treatments, which includes any prescription medicine you use regularly. Failing to disclose this could invalidate a claim.

Beyond disclosure, there are practical questions: will the policy cover the cost of replacement medicine if a pen is lost, damaged or stolen abroad? Will it cover treatment needed as a result of a side effect that requires medical attention in another country? The answers vary by insurer and policy tier. Our guide to weight loss injections and travel insurance covers these questions in detail, including storage requirements during travel and how to carry pens through airport security. It's a genuinely underread topic for people who start treatment and then have a summer trip planned.

Choosing how to fund weight loss injections: the factors that matter

Framing this as a simple cost question misses most of what's relevant. The more useful questions are: Is the supply chain verified and regulated? Is a qualified prescriber conducting a real clinical assessment, not a checkbox form? Is there clinical oversight if your health changes or a side effect needs attention?

For anyone considering a private route, the GPhC pharmacy register lets you verify that any online pharmacy dispensing these medicines holds a current registration. It takes thirty seconds and is the single most reliable check available. Weight loss injections such as Mounjaro and Wegovy are prescription-only medicines; a legitimate service will always require a prescriber assessment before dispensing, full stop.

At nume, one transparent price covers the consultation, the prescription, the medicine and free next-working-day delivery. There is no subscription and no auto-renewal. Every repeat order is clinically reviewed before anything is sent out. If you want to understand whether you're likely to be clinically suitable, our prescribers (you can read about the clinical team at our clinical lead's profile) review every consultation the same day it's submitted. You can also learn more about how insulin injections for weight loss compare to GLP-1 options if you have questions about which approach suits your circumstances, or read our dedicated page on injection for insulin resistance and weight loss if that is relevant to your health background. Start your free consultation here and a real prescriber will read it.